Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$8.64
$0.62(8.37%)
At close: 4:00 PM EDT
$8.64
$0.62(8.37%)
Day’s Range― - ―
52-Week Range$5.61 - $13.67
Previous CloseN/A
Volume420.10K
Average Volume (3M)920.00K
Market Cap
$360.55M
Enterprise Value$376.16M
Total Cash (Recent Filing)$199.43M
Total Debt (Recent Filing)$33.00M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Nov 18, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding61,843,445
10 Day Avg. Volume883,531
30 Day Avg. Volume920,002
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.07K
Enterprise Value/Ebitda-2.52
Forecast
1Y Price Target
$30.33Price Target Upside251.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy And SafetySustained clinical improvements and favorable safety across follow-up support miv-cel’s potential differentiation in autoimmune cell therapy. If durability continues, the data could strengthen regulatory progress, adoption prospects, and Kyverna’s platform position over the next several quarters.
Long-term Manufacturing ReadinessSecuring multi-year manufacturing capacity reduces a major execution hurdle for a clinical-stage cell therapy company. Flexible supply and testing support ongoing trials and potential commercialization, while the established partnership improves readiness if regulatory milestones are achieved.
Relatively Modest LeverageRelatively low debt leverage provides more balance-sheet flexibility than a heavily debt-funded structure would offer. This can help Kyverna direct capital toward clinical development and manufacturing while limiting the immediate burden of debt service on already constrained resources.
Bears Say
No Commercial RevenueThe absence of commercial revenue means Kyverna has not yet demonstrated a recurring product-based funding model. Operations therefore remain dependent on development progress and external capital until a therapy is approved and commercial sales can begin.
Heavy And Persistent Cash BurnLarge, persistent operating and free-cash-flow deficits indicate substantial funding needs while the pipeline advances. Continued cash consumption can constrain investment choices and increase reliance on additional financing before the company reaches a potential revenue-generating stage.
Widening Losses And Shrinking Equity CushionExpanding losses are eroding the company’s equity base and reducing the financial cushion available to absorb delays or higher development costs. The decline also points to ongoing capital-consumption and potential dilution pressure as Kyverna funds its pipeline.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $5.61 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $360.55M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 28 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.678 by $0.048.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.69.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 61,843,445 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.678. Following the earnings report the stock price went up 0.374%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.33 (251.08% Upside)
$30.33 (251.08% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 12.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.46%
12-Months-Change
Fundamentals
Return on Equity
-81.91%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.33
▲(251.08% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
22.84% Insiders
5.77% Mutual Funds
0.02% Other Institutional Investors
61.82% Public Companies and
Individual Investors